We found that immunity-low included a higher percentage of IDH-mutated LGGs than immunity-high, while immunity-high included a higher percentage of IDH-wildtype LGGs than immunity-low (Fisher’s exact test, P < 0.001) (Fig. 1) in TCGA-glioma. Here, IDH1 is linked to central nervous system cancer.